HC Wainwright Begins Coverage on Alpha Cognition (NASDAQ:ACOG)

Stock analysts at HC Wainwright started coverage on shares of Alpha Cognition (NASDAQ:ACOG) in a research report issued on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $20.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 250.88% from the company’s previous close.

Alpha Cognition Stock Performance

Shares of ACOG opened at $5.70 on Tuesday. Alpha Cognition has a 52-week low of $4.66 and a 52-week high of $7.00. The firm has a fifty day simple moving average of $5.92. The company has a market cap of $91.31 million, a price-to-earnings ratio of -2.23 and a beta of 2.50.

Hedge Funds Weigh In On Alpha Cognition

Several hedge funds and other institutional investors have recently modified their holdings of the business. Sphera Funds Management LTD. bought a new position in shares of Alpha Cognition in the 4th quarter valued at $3,652,000. Bleichroeder LP bought a new position in shares of Alpha Cognition in the 4th quarter valued at $1,024,000. Alyeska Investment Group L.P. bought a new position in shares of Alpha Cognition in the 4th quarter valued at $2,356,000. Manatuck Hill Partners LLC bought a new stake in Alpha Cognition during the 4th quarter worth $395,000. Finally, Tudor Investment Corp ET AL bought a new stake in Alpha Cognition during the 4th quarter worth $412,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.